Effectiveness and safety of reduced dose prasugrel versus standard dose ticagrelor in East Asian patients with acute coronary syndrome undergoing percutaneous coronary intervention

被引：0
|
作者：
Huang, Hsin-Yi [1 ]
Wang, Chi-Chuan [1 ]
Wu, Yee-Jen [2 ]
Wu, Chien-Chih [2 ]
Huang, Ling-Ya [1 ]
机构：
[1] Natl Taiwan Univ, Sch Pharm, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Pharm, Taipei, Taiwan
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
53
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [1] Low-dose prasugrel versus standard-dose ticagrelor in east Asian patients with acute coronary syndrome
    Wu, Yee-Jen
    Wu, Chien-Chih
    Huang, Hsin-Yi
    Wu, Chi-Yun
    Huang, Ching-Chang
    Wang, Chi-Chuan
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2024, 57 (04) : 537 - 546
  • [2] Low-dose prasugrel versus standard-dose ticagrelor in east Asian patients with acute coronary syndrome
    Yee-Jen Wu
    Chien-Chih Wu
    Hsin-Yi Huang
    Chi-Yun Wu
    Ching-Chang Huang
    Chi-Chuan Wang
    Journal of Thrombosis and Thrombolysis, 2024, 57 : 537 - 546
  • [3] Ticagrelor versus Adjusted-Dose Prasugrel in Acute Coronary Syndrome with Percutaneous Coronary Intervention
    Tsai, Ming-Lung
    Lin, Yuan
    Chen, Dong-Yi
    Lin, Ming-Shyan
    Wang, Chao-Yung
    Hsieh, I-Chang
    Yang, Ning-, I
    Hung, Ming-Jui
    Chen, Tien-Hsing
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (03) : 747 - 756
  • [4] Comparative effectiveness and safety of prasugrel versus ticagrelor in patients with acute coronary syndrome undergoing percutaneous transluminal coronary angioplasty
    Ray, Avik
    Najmi, Ahmad
    Khandelwal, Gaurav
    Jhaj, Ratinder
    Sadasivam, Balakrishnan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 177 - 177
  • [5] Ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An unresolved issue
    Savarese, Gianluigi
    Lund, Lars H.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 249 : 77 - 78
  • [6] Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention
    Coughlan, J. J.
    Aytekin, Alp
    Ndrepepa, Gjin
    Schuepke, Stefanie
    Bernlochner, Isabell
    Mayer, Katharina
    Neumann, Franz Josef
    Menichelli, Maurizio
    Richardt, Gert
    Woehrle, Jochen
    Witzenbichler, Bernhard
    Gewalt, Senta
    Xhepa, Erion
    Kufner, Sebastian
    Sager, Hendrik B.
    Joner, Michael
    Ibrahim, Tareq
    Fusaro, Massimiliano
    Laugwitz, Karl Ludwig
    Schunkert, Heribert
    Kastrati, Adnan
    Cassese, Salvatore
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2021, 14 (07) : E010565
  • [7] Prasugrel or Ticagrelor for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Does it Matter?
    Giri, Jay
    Nathan, Ashwin
    JACC-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (16) : 1587 - 1589
  • [8] Safety and efficacy of low-dose ticagrelor in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention
    Wang, Yue
    Liu, Beibei
    Chen, Leilei
    Wang, Yue
    Wang, Zhiqiang
    Zhang, Xiaojiang
    Suo, Min
    Mintz, Gary S.
    Wu, Xiaofan
    PLATELETS, 2022, 33 (02) : 304 - 311
  • [9] Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Analysis from the Acute Coronary Syndrome Israeli Survey
    Eliaz, Ran
    Mengesha, Bethlehem
    Ovdat, Tal
    Iakobishvili, Zaza
    Hasdai, David
    Kheifets, Mark
    Klempfner, Robert
    Beigel, Roy
    Kalmanovich, Eran
    Alcalai, Ronny
    Levi, Amos
    CARDIOLOGY, 2022, 147 (02) : 113 - 120
  • [10] Prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention
    Deepak L. Bhatt
    Current Atherosclerosis Reports, 2008, 10 (5) : 367 - 368
12345